INAB IN8BIO INC

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45th  Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at .

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit .

Investor & Corporate Contact

Glenn Schulman, PharmD, MPH

IN8bio, Inc.

203.494.7411

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744



EN
26/02/2025

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Trea...

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recen...

2h / 1m 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GB...

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving...

June 2, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T C...

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γδ T cells (Vδ1+ and Vδ2+), overcoming one of the critical challenges in pa...

May 14, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell ...

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- . (...

May 12, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports First Quarter 2025 Financial Results and Recent Busines...

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT) Meetings On May 1st, 2025, we celebrated the 5th anniversary of the first patient ever treated with a gamma-delta T cell therapy being developed by IN8bio. This older patient with complex AML and multiple genetic a...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch